Drug Trial Radar · NCT01257906
Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo
Last checked: Nov 19, 2026Latest source record: Dec 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,225
Actual
Start
May 2010
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Actavis Mid-Atlantic LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 10, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of clindamycin phosphate (1.2%) and tretinoin (0.025%) topical gel and the current study is designed to evaluate the bioequivalence of this formulation to ZIANA®.
Conditions
- MILD TO SEVERE ACNE VULGARIS
Interventions
CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GELDrug
Topical Gel applied in the evening for 84 days
ZIANA®Drug
Topical Gel applied in the evening for 84 days
Vehicle ControlDrug
Topical Gel applied in the evening for 84 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Therapeutic EquivalenceTime frame: 12-weeks
- SuperiorityTime frame: 12-Weeks
- SafetyTime frame: 12-Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lotus Labs Pvt. Ltd
Bangalore, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.